CRISPR Therapeutics holds a consensus "Hold" rating with an average target price of $74.94. CEO Samarth Kulkarni recently sold 30,000 shares at $55.62, reducing his stake by 13.24%. The company reported a quarterly loss of $1.01 per share, surpassing estimates, with revenue of $0.60 million. Insider sales totaled 50,382 shares valued at $2.74 million in the last 90 days, while institutional investors own 69.20% of the stock. The stock traded at $51.94, with a 52-week range of $43.42 to $91.10.